Allterum Therapeutics
PrivateLast Round
Grant
Sep 9, 2025
Total Funding Raised
$22.42M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Allterum Therapeutics is a clinical-stage biotechnology company developing a monoclonal antibody targeting the interleukin-7 receptor for the treatment of cancers such as Acute Lymphoblastic Leukemia (ALL).
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Allterum Therapeutics Comparables
Compare Allterum Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Gyala Therapeutics | 74% | |
| PeproMene Bio | 71% | |
| Xencor, Inc. | 70% |
Allterum Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Sep 9, 2025 | ||||
| Grant | Jun 13, 2025 | ||||
| Grant | Apr 8, 2024 | ||||
| Grant | Jul 19, 2023 | ||||
| Seed | Dec 17, 2020 | ||||
Grant | Apr 21, 2020 |
Allterum Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| Cancer Prevention & Research Institute of Texas | Grant |
| NIH RADx | Grant |
| Fannin Innovation Studio | Seed |
| Cancer Prevention and Research Institute of Texas | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 29, 2026
Monthly visitors grew 270% MoM, from 398 to 1.5K.
- May 18, 2026
Monthly visitors increased 109% MoM.
Allterum Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Allterum Therapeutics's valuation, stock price, and market status.
Is Allterum Therapeutics a public or private company?
Allterum Therapeutics is a private company.
What is the current stock price of Allterum Therapeutics?
Allterum Therapeutics is a private company, so its shares have no public market price. Caplight tracks Allterum Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Allterum Therapeutics worth (valuation)?
Valuation information for Allterum Therapeutics is not publicly available.
Can I buy Allterum Therapeutics stock?
Allterum Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Allterum Therapeutics's last funding round?
Allterum Therapeutics's most recent funding round was Grant on September 9, 2025.
Who are the main investors in Allterum Therapeutics?
Key investors in Allterum Therapeutics include National Cancer Institute, Cancer Prevention & Research Institute of Texas, NIH RADx, Fannin Innovation Studio, Cancer Prevention and Research Institute of Texas.
Will Allterum Therapeutics IPO soon?
No public IPO plans have been announced for Allterum Therapeutics.
How can I track Allterum Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Allterum Therapeutics's shares on secondary markets.